title: Induction of fetal globin in beta-thalassemia: Cellular obstacles and molecular progress.
abstract: Accelerated apoptosis of erythroid progenitors in beta-thalassemia is a significant barrier to definitive therapy because the beneficial effects of fetal globin-inducing agents on globin chain balance may not be inducible in cells in which programmed cell death is established early. Accordingly, our objectives have been to identify methods to decrease cellular apoptosis and to identify orally tolerable fetal globin gene inducers. A pilot clinical trial was conducted to determine whether combined use of a fetal globin gene inducer (butyrate) and rhu-erythropoietin (EPO), the hematopoietic growth factor that prolongs erythroid cell survival and stimulates erythroid proliferation, would produce additive hematologic responses in any thalassemia subjects. Butyrate and EPO were administered in 10 patients. Novel fetal globin gene inducers that also stimulate erythroid proliferation were evaluated for pharmacokinetic profiles. Patients with beta+-thalassemia had relatively low levels of endogenous EPO (<145 mU/mL) and had additive responses to administered EPO and butyrate. Patients with at least one beta 0-globin mutation had higher baseline HbF levels (>60%) and EPO levels (>160 mU/mL), and three-fourths of these subjects responded to the fetal globin gene inducer alone. A few select fetal globin-inducing short-chain fatty acid derivatives that stimulated cell proliferation also had favorable pharmacokinetics. These studies identify a significant subset of thalassemia patients who appear to require exogenous EPO to respond optimally to any HbF inducer, as well as new therapeutic candidates that act on both cellular and molecular pathologies of beta-thalassemia. Both approaches now offer excellent potential for tolerable, definitive treatment of beta-thalassemia.
authors.affiliation: Hemoglobinopathy-Thalassemia Research Unit, Boston University School of Medicine, 80 E. Concord St., L-908, Boston, MA 02118, USA. sperrine@bu.edu
authors.forename: Susan P
authors.initials: SP
authors.lastname: Perrine
authors.forename: Serguei A
authors.initials: SA
authors.lastname: Castaneda
authors.forename: Michael S
authors.initials: MS
authors.lastname: Boosalis
authors.forename: Gary L
authors.initials: GL
authors.lastname: White
authors.forename: Brandon M
authors.initials: BM
authors.lastname: Jones
authors.forename: Regine
authors.initials: R
authors.lastname: Bohacek
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001803:Blood Transfusion; D002087:Butyrates / Q000008:administration & dosage / Q000627:therapeutic use*; D002478:Cells, Cultured / Q000187:drug effects; D003131:Combined Modality Therapy; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D041905:Erythroid Cells / Q000187:drug effects* / Q000378:metabolism; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D005232:Fatty Acids, Volatile / Q000493:pharmacokinetics / Q000494:pharmacology; D005319:Fetal Hemoglobin / Q000096:biosynthesis* / Q000235:genetics; D015870:Gene Expression / Q000187:drug effects*; D006801:Humans; D010215:Papio; D010865:Pilot Projects; D011994:Recombinant Proteins; D016896:Treatment Outcome; D017086:beta-Thalassemia / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000628:therapy
chemical_list: D002087:Butyrates; D005232:Fatty Acids, Volatile; D011994:Recombinant Proteins; D004921:Erythropoietin; D005319:Fetal Hemoglobin